Incyte Corporation (INCY)
INCY Stock Price Chart
Explore Incyte Corporation interactive price chart. Choose custom timeframes to analyze INCY price movements and trends.
INCY Company Profile
Discover essential business fundamentals and corporate details for Incyte Corporation (INCY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Nov 1993
Employees
2.62k
Website
https://www.incyte.comCEO
William J. Meury
Description
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
INCY Financial Timeline
Browse a chronological timeline of Incyte Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Jul 2026
EPS estimate is $2.09, while revenue estimate is $1.46bn.
Earnings released on 28 Apr 2026
EPS came in at $1.81 surpassing the estimated $1.34 by +35.07%, while revenue for the quarter reached $1.27bn , beating expectations by +4.66%.
Earnings released on 10 Feb 2026
EPS came in at $1.80 falling short of the estimated $1.90 by -5.26%, while revenue for the quarter reached $1.51bn , beating expectations by +11.22%.
Earnings released on 28 Oct 2025
EPS came in at $2.26 surpassing the estimated $1.66 by +36.14%, while revenue for the quarter reached $1.37bn , beating expectations by +0.87%.
Earnings released on 29 Jul 2025
EPS came in at $1.57 surpassing the estimated $1.39 by +12.95%, while revenue for the quarter reached $1.22bn , missing expectations by -3.29%.
Earnings released on 29 Apr 2025
EPS came in at $1.16 surpassing the estimated $1.01 by +14.85%, while revenue for the quarter reached $1.05bn , missing expectations by -8.68%.
Earnings released on 10 Feb 2025
EPS came in at $1.43 falling short of the estimated $1.57 by -8.92%, while revenue for the quarter reached $1.18bn , beating expectations by +17.30%.
Earnings released on 29 Oct 2024
EPS came in at $1.07 falling short of the estimated $1.12 by -4.46%, while revenue for the quarter reached $1.14bn , missing expectations by -0.51%.
Earnings released on 30 Jul 2024
EPS came in at -$1.82 falling short of the estimated $0.78 by -333.33%, while revenue for the quarter reached $1.04bn , beating expectations by +1.77%.
Earnings released on 30 Apr 2024
EPS came in at $0.64 falling short of the estimated $0.84 by -23.81%, while revenue for the quarter reached $880.89m , missing expectations by -4.45%.
Earnings released on 13 Feb 2024
EPS came in at $1.06 falling short of the estimated $1.16 by -8.62%, while revenue for the quarter reached $1.01bn , beating expectations by +1.12%.
Earnings released on 31 Oct 2023
EPS came in at $1.10 surpassing the estimated $1.09 by +0.92%, while revenue for the quarter reached $919.03m , missing expectations by -4.95%.
Earnings released on 1 Aug 2023
EPS came in at $0.99 surpassing the estimated $0.83 by +19.28%, while revenue for the quarter reached $954.61m , beating expectations by +4.87%.
Earnings released on 2 May 2023
EPS came in at $0.37 falling short of the estimated $0.85 by -56.47%, while revenue for the quarter reached $808.67m , missing expectations by -5.70%.
Earnings released on 7 Feb 2023
EPS came in at $0.62 surpassing the estimated $0.59 by +5.08%, while revenue for the quarter reached $926.70m , beating expectations by +5.52%.
Earnings released on 1 Nov 2022
EPS came in at $0.60 falling short of the estimated $0.72 by -16.67%, while revenue for the quarter reached $823.30m , missing expectations by -2.30%.
Earnings released on 2 Aug 2022
EPS came in at $1.01 surpassing the estimated $0.79 by +27.85%, while revenue for the quarter reached $911.40m , beating expectations by +11.35%.
Earnings released on 3 May 2022
EPS came in at $0.55 falling short of the estimated $0.57 by -3.51%, while revenue for the quarter reached $733.24m , missing expectations by -2.23%.
Earnings released on 8 Feb 2022
EPS came in at $0.10 falling short of the estimated $0.84 by -88.10%, while revenue for the quarter reached $862.85m , beating expectations by +6.20%.
Earnings released on 2 Nov 2021
EPS came in at $1.18 surpassing the estimated $0.76 by +55.26%, while revenue for the quarter reached $812.99m , beating expectations by +48.15%.
Earnings released on 3 Aug 2021
EPS came in at $0.80 surpassing the estimated $0.74 by +8.11%, while revenue for the quarter reached $705.71m , beating expectations by +2.89%.
INCY Stock Performance
Access detailed INCY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
